Phase II trial of PALA in hypernephroma and urinary bladder cancer.
D000230:Adenocarcinoma / Q000188:drug therapy*; D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D009362:Neoplasm Metastasis; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D009943:Organophosphorus Compounds; D001224:Aspartic Acid; C013195:sparfosic acid; D010746:Phosphonoacetic Acid